Clinical Trials Logo

Clinical Trial Summary

All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.


Clinical Trial Description

All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.

1. Primary objective:

- To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by,

- Adverse events and serious adverse events (non-specific and radiation specific)

- Changes in liver function parameters

- To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best overall response rate after SIRT

2. Secondary objectives:

- To observe the efficacy of SIRT by,

- Overall survival (OS)

- Overall/objective response rate (ORR)

- Time-to-progression

- Time-to-liver progression

- Progression-free survival

- To observe the changes in clinical presentation after SIRT by,

- ECOG score

- Child-Pugh score

- Percentage of subjects with down-staging or down-sizing of treated lesion to resection, transplantation, or radiofrequency ablation (RFA)

- To observe the practice pattern of SIRT by,

- Median dosage (GBq)

- Number of SIRT sessions received by subjects

3. Exploratory objectives:

- To explore prognostic factors for disease progression after SIRT by comparing the following parameters:

- Number of tumors in subjects prior to SIRT

- Median tumor size in subjects prior to SIRT

- Location of tumor in subjects treated with SIRT (hepatic segment or lobe)

- Number of prior TACE treatment in subjects

- Antiviral therapy subjects HCC ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03292991
Study type Observational [Patient Registry]
Source Taipei Veterans General Hospital, Taiwan
Contact Rheun-Chuan Lee, M.D.
Phone +886-2-28712121
Email vghtpeyttrium90@gmail.com
Status Recruiting
Phase N/A
Start date June 9, 2015
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2